Bladder cancer is one of the more common cancers worldwide. It is considered a major health care problem with a high financial burden. Of these cases, 75% are non-muscle-invasive, which characterizes ...
The novel intravesical drug delivery system releases erdafitinib locally within the bladder while limiting systemic toxicities. Findings from the first-in-human study of TAR-210 were presented at the ...
Selective bladder preservation after neoadjuvant zanidatamab combined with tislelizumab and chemotherapy in patients with HER2-positive muscle-invasive bladder cancer (HARBOR): A multicenter study.
Clinical impacts of the 2025 Southern California wildfires among childhood cancer patients and survivors: A pilot study. Indirect cost per visit ($) – Model 1, median (IQR) 100 (72–112) Indirect cost ...
NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...
CHICAGO -- An investigational intravesical delivery system designed to provide sustained local release of gemcitabine into the bladder produced high rates of complete response (CR) in ...
Cisplatin-based NAC and AMVAC improved two-year MFS in MIBC patients, with a 72.9% overall MFS rate. 17% of all patients and 48% in the AS group avoided cystectomy without metastatic disease. Severe ...
Researchers at Weill Cornell Medicine, Cedars-Sinai Medical Center and Roswell Park Comprehensive Cancer Center have ...
SunRISe-4 evaluated neoadjuvant gemcitabine intravesical system (TAR-200) plus cetrelimab or cetrelimab monotherapy for pathologic complete response in patients with MIBC ineligible for or refusing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results